TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $12.08 Average PT from Analysts

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has received an average rating of “Buy” from the nine analysts that are presently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $11.79.

Several brokerages have recently weighed in on TLSI. Oppenheimer began coverage on shares of TriSalus Life Sciences in a research note on Monday, September 16th. They set an “outperform” rating and a $10.00 target price for the company. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Roth Mkm assumed coverage on TriSalus Life Sciences in a research note on Monday, November 11th. They issued a “buy” rating and a $11.00 target price on the stock. Cantor Fitzgerald initiated coverage on TriSalus Life Sciences in a research note on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price target for the company. Finally, Canaccord Genuity Group lowered their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 15th.

TriSalus Life Sciences Price Performance

Shares of NASDAQ:TLSI opened at $4.05 on Friday. TriSalus Life Sciences has a 1-year low of $3.50 and a 1-year high of $10.42. The stock has a market cap of $123.48 million, a P/E ratio of -1.63 and a beta of 0.56. The firm has a fifty day moving average price of $4.14 and a 200 day moving average price of $4.92.

Insider Buying and Selling at TriSalus Life Sciences

In related news, major shareholder Equity Ab Frankenius bought 62,972 shares of the company’s stock in a transaction on Tuesday, December 17th. The stock was bought at an average cost of $3.97 per share, with a total value of $249,998.84. Following the completion of the acquisition, the insider now owns 6,230,748 shares in the company, valued at approximately $24,736,069.56. This represents a 1.02 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders acquired 70,012 shares of company stock valued at $281,235. 32.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors and hedge funds have recently modified their holdings of the company. Walleye Capital LLC acquired a new position in TriSalus Life Sciences during the third quarter worth $66,000. Virtu Financial LLC purchased a new position in shares of TriSalus Life Sciences in the third quarter valued at $92,000. Vestcor Inc purchased a new position in shares of TriSalus Life Sciences in the third quarter valued at $108,000. MSD Partners L.P. acquired a new position in shares of TriSalus Life Sciences during the 3rd quarter worth $184,000. Finally, Wolverine Asset Management LLC purchased a new stake in shares of TriSalus Life Sciences in the 2nd quarter worth about $240,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.